Drug Profile
WIN 62005
Latest Information Update: 06 Aug 1998
Price :
$50
*
At a glance
- Originator Sanofi Winthrop
- Class Heart failure therapies
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 06 Aug 1998 No-Development-Reported for Heart failure in USA (Unknown route)
- 31 Jan 1995 New profile
- 31 Jan 1995 Preclinical development for Heart failure in USA (Unknown route)